{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056248","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.142319+00:00","generated_at":"2026-06-02T05:17:29.905641+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025","bullets":["Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.","Cash, equivalents and marketable securities $239M after $161.8M public offering; runway extended into 2026.","Positive Phase 2 dose exploration: nomlabofusp generally well-tolerated, dose-dependent frataxin increases in skin and buccal cells.","First patient dosed in open-label extension (OLE) study of 25 mg daily; interim data on track for Q4 2024.","BLA submission targeted second half 2025; FDA discussions underway for accelerated approval using frataxin as surrogate endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056248","json":"https://secwatch.observer/filing/0000950170-24-056248.json","markdown":"https://secwatch.observer/filing/0000950170-24-056248.md","text":"https://secwatch.observer/filing/0000950170-24-056248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/0000950170-24-056248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/lrmr-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:17:29.905641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"641fb18e21cea127964ea13c8542a806e84cd2e0","claim":"Larimar Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $14.7 million, EPS $0.27 per share.","evidence_excerpt":"The Company reported a net loss for the first quarter of 2024 of $14.7 million, or $0.27 per share, compared to a net loss of $6.5 million, or $0.15 per share, for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/0000950170-24-056248-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$14.7 million"},{"label":"EPS","value":"$0.27 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}